Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8633052 | 0.82 | CACNA1B (0.45) | CACNA1BMAPTEPHX2HPGDALDH1A1 | |
| SCHEMBL14330745 | 0.76 | SLC6A3 (0.36) | MEN1KMT2A | |
| SCHEMBL2049993 | 0.75 | ALDH1A1 (0.38) | CACNA1BALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL14320845 | 0.75 | ALDH1A1 (0.38) | CACNA1BALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL11255018 | 0.74 | CACNA1B (0.42) | CACNA1BMAPTEPHX2HPGDSMN1; SMN2 | |
| SCHEMBL3278746 | 0.73 | MEN1 (0.40) | EPHX2ALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL14331616 | 0.72 | ALDH1A1 (0.45) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL10963986 | 0.72 | CACNA1B (0.40) | CACNA1BMAPTEPHX2MEN1KMT2A | |
| SCHEMBL11219328 | 0.72 | ALDH1A1 (0.47) | CACNA1BEPHX2ALDH1A1GAASMN1; SMN2 | |
| SCHEMBL11092885 | 0.71 | CACNA1B (0.40) | CACNA1BMAPTEPHX2HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120328518-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS | PIRAMAL IMAGING SA (CH) | 2012-12-27 | — | — | US | disclosed |
| US-20120328518-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS | PIRAMAL IMAGING SA (CH) | 2012-12-27 | — | — | US | disclosed |
| EP-2338892-A1 | Prostate specific membrane antigen inhibitors | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120328518-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS | KLK3, FOLH1, ACP3 | CACNA1B 2605/4885MAPT 1467/4885EPHX2 3758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.